Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity

PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010

Roche completes enrollment in RG7128 Phase 2b PROPEL study

Roche completes enrollment in RG7128 Phase 2b PROPEL study

FDA grants approval for Abbott's antiretroviral medication Norvir

FDA grants approval for Abbott's antiretroviral medication Norvir

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Controversy around Merck's pricing for its AIDS drug Isentress

Controversy around Merck's pricing for its AIDS drug Isentress

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

AstraZeneca's CRESTOR receives favorable vote from FDA Advisory Committee

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Tibotec Therapeutics'  INTELENCE granted FDA traditional approval

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

Pfizer’s Revatio Injection receives FDA approval

Pfizer’s Revatio Injection receives FDA approval

On-going Phase 2b study conducted by Roche of ITMN-191 modified

On-going Phase 2b study conducted by Roche of ITMN-191 modified

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Interim data from Schering-Plough's narlaprevir Phase IIa study

Interim data from Schering-Plough's narlaprevir Phase IIa study

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

Novel HIV drug to be studied in cell cultures and patients

Novel HIV drug to be studied in cell cultures and patients

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients